Richard Vincent
Follow
Get notifications in MyBN when activity occurs.
Richard Vincent
Chief Executive, Managing Director / Australian Pharmaceutical Industries
Richard Vincent began his professional career in finance with Bridgestone before moving to Britax Rainsfords where he was chief financial officer. He was with FH Faulding & Co from 1998 to 2005 and held a number of senior leadership roles including responsibility for the pharmacy distribution, retail merchandise and generic pharmaceutical development.
Mr Vincent joined Australian Pharmaceutical Industries in 2005 where he held a number of general management roles that have included pharmacy distribution, strategy, supply chain, franchise recruitment, IT, manufacturing and mergers and acquisition. He became chief executive and managing director in February 2017.
Mr Vincent joined Australian Pharmaceutical Industries in 2005 where he held a number of general management roles that have included pharmacy distribution, strategy, supply chain, franchise recruitment, IT, manufacturing and mergers and acquisition. He became chief executive and managing director in February 2017.
Lists and Charts
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Person Activity
| NEW ROLE: Chief Executive, Managing Director, Australian Pharmaceutical Industries | 03 Nov 2020 |
Related Information
Positions - Current
| Position | Company | Year | Company's current rank | WA staff |
|---|---|---|---|---|
| Chief Executive, Managing Director | | 2017 |
Positions - Previous
| Position | Company | Year | Company's current rank |
|---|---|---|---|
| Group General Manager, Business Development & Operations | | 2005 - 2017 |
Directors Interests
| Company | Date | Transaction type | Number of shares | Price per share | Transaction value | Nature of change |
|---|---|---|---|---|---|---|
| Australian Pharmaceutical Industries | 29 Mar 2022 | Other | 2,213,741 | $1.55 | $3,431,299 | OtherCancellation of securities |
| Australian Pharmaceutical Industries | 08 Feb 2022 | Issued | 731,730 | OtherIssue of securities: 22,13,741 - performance rights | ||
| Australian Pharmaceutical Industries | 15 Oct 2021 | Other | 416,954 | OtherAs advised by the company: 1,482,011 - Performance RightsPerformance rights lapsed under API's LongTerm Incentive Plan | ||
| Australian Pharmaceutical Industries | 15 Oct 2021 | Issued | 160,900 | OtherIssue of securities: 1,898,965 - performance rights | ||
| Australian Pharmaceutical Industries | 03 Feb 2021 | Issued | 825,400 | OtherIssue of securities: 1,738,065 - performance rights |
Powered by Morningstar ®
